Article
Novel structural CYP51 mutation in Trypanosoma cruzi associated with multidrug resistance to CYP51 inhibitors and reduced infectivity.
International journal for parasitology. Drugs and drug resistance - 1 Aug 2020
Franco Caio H, Warhurst David C, Bhattacharyya Tapan, Au Ho Y A, Le Hai, Giardini Miriam A, Pascoalino Bruno S, Torrecilhas Ana Claudia, Romera Lavinia M D, Madeira Rafael Pedro, Schenkman Sergio, Freitas-Junior Lucio H, Chatelain Eric, Miles Michael A, Moraes Carolina B
Abstract excerpt
Ergosterol biosynthesis inhibitors, such as posaconazole and ravuconazole, have been proposed as drug candidates for Chagas disease, a neglected infectious tropical disease caused by the protozoan parasite Trypanosoma cruzi. To understand better the mechanism of action and resistance to these inhibitors, a clone of the T. cruzi Y strain was cultured under intermittent and increasing concentrations of ravuconazole...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.